Vanda says FDA grants rare pediatric disease designation for CMT2S therapy VCA-894A

• Vanda received FDA Rare Pediatric Disease Designation for VCA-894A, an investigational antisense oligonucleotide for Charcot-Marie-Tooth disease type 2S.
• The designation could support eligibility for a Rare Pediatric Disease Priority Review Voucher if a qualifying marketing application is later approved.
• VCA-894A targets a patient-specific CMT2S variant; the company plans to continue development discussions with the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607071630PR_NEWS_USPR_____PH99380) on July 07, 2026, and is solely responsible for the information contained therein.